Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. - Wikidata - wikimedia - TriplyDB

Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma.

Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma.

http://www.wikidata.org/entity/Q35289603

about

HVPG signature: A prognostic and predictive tool in hepatocellular carcinoma Epigenetic regulation of insulin-like growth factor axis in hepatocellular carcinoma Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?Targeting the insulin-like growth factor pathway in hepatocellular carcinoma Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma Insufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1α/VEGFA Cross-species array comparative genomic hybridization identifies novel oncogenic events in zebrafish and human embryonal rhabdomyosarcoma Validation of a Preclinical Model of Diethylnitrosamine-Induced Hepatic Neoplasia in Yucatan Miniature Pigs Reassessing hepatocellular carcinoma staging in a changing patient population.Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma.Targeting insulin-like growth factor axis in hepatocellular carcinoma.Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study.The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets.Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma.IGF-II Producing Hepatocellular Carcinoma Treated with Sorafenib: Metabolic Complications and a Foresight to Molecular Targeting Therapy to the IGF Signal Up-regulation of microRNA-190b plays a role for decreased IGF-1 that induces insulin resistance in human hepatocellular carcinoma.Serum insulin-like growth factor-1 predicts disease progression and survival in patients with hepatocellular carcinoma who undergo transarterial chemoembolization.Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1 Prostate tumor overexpressed 1 is a novel prognostic marker for hepatocellular carcinoma progression and overall patient survival.Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma.Validation of a Modified Child-Turcotte-Pugh Classification System Utilizing Insulin-Like Growth Factor-1 for Patients with Hepatocellular Carcinoma in an HBV Endemic Area.Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma High expression of myofibrillogenesis regulator-1 predicts poor prognosis for patients with hepatocellular carcinoma after curative hepatectomy Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma.Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance.Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma Human growth hormone and human prolactin function as autocrine/paracrine promoters of progression of hepatocellular carcinoma Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment.Isoflurane anesthesia induces liver injury by regulating the expression of insulin-like growth factor 1.Circulating markers for prognosis of hepatocellular carcinoma.Review of angiogenesis in hepatocellular carcinoma.TNM/Okuda/Barcelona/UNOS/CLIP International Multidisciplinary Classification of Hepatocellular Carcinoma: concepts, perspectives, and radiologic implications.Staging systems of hepatocellular carcinoma: a review of literature.Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis.Staging systems for hepatocellular carcinoma: Current status and future perspectives Non-alcoholic fatty liver disease-related hepatocellular carcinoma: a sleeping tiger in the Asia Pacific.Prognostic significance of serum insulin-like growth factor-1 in patients with hepatocellular carcinoma following transarterial chemoembolization Magnetic resonance imaging with gadoxetic acid for local tumour progression after radiofrequency ablation in patients with hepatocellular carcinoma.

P2860

Q26738597-E76CD665-212F-45BB-A768-0B6CB0E978D9 Q26766068-75662E3E-9039-4301-B4B1-21FA2361D467 Q26783895-72ED4CC2-17AB-40E5-8F93-64F41969C7FC Q26784218-A9F84C36-9F31-4AE5-8AA0-8BC80C2EF2B4 Q27006846-0A3EF2A3-CD3E-4CDE-9785-4FE908D531E1 Q28080514-6940AC17-5392-4DF4-BB45-E02E03D5926A Q28483727-F90A78A8-BEAA-4340-B841-823EC37C1C95 Q28536066-2B6C1B68-E6C2-4137-9063-B54B194981B2 Q33688431-1D3637F5-DBE0-4EA1-9FE0-10DA655280D1 Q33767286-4FBA7A10-C99A-4414-B916-938FD3CD9324 Q33859804-B4B3D6AE-04BC-469D-A796-0F324DBD06B2 Q33951057-B3B8CC68-747B-445D-BFFD-841D5C0FBBF9 Q33957406-90276748-8B04-4F42-8F0C-350B5A1DDED7 Q34182483-D7D1D38A-5AFB-4981-A1F4-FD6E4D03E120 Q34525541-C69E82C0-F7FA-4521-928C-E25A0A5AE4AA Q34647501-1FB63EE7-B1D5-4BB7-A287-5678173C1083 Q35107341-7EFC5086-59D6-4F40-BBC3-620E5EFDBA53 Q35111392-B1A085C8-26DC-4644-8C1A-A74F8A0E758F Q36019476-602CE764-D8D6-41DA-AEA8-08CAFF405BEC Q36153245-BE47EF04-7479-4BD1-AD8B-715A879A110C Q36182824-8B2C55C4-1C85-4481-A7BC-09784AED0B17 Q36255571-C13052E4-4F51-48DE-89CB-2935F24DE758 Q36356282-34B256A9-C3E3-4525-8F5E-471D760AD053 Q36464650-983BE29C-6D6E-48D5-B224-D8AE08F5619D Q36652018-C42F5FF9-1E81-48D6-AE39-F2B76815B332 Q37013991-CFD426CC-5A86-43C8-8188-CC8A75E64B17 Q37088265-CAB98807-21F4-48D2-9C6E-BFD727BB4DFE Q37179530-B273547A-51FE-446D-8B0D-88691058A381 Q37301860-044D04D6-2A7C-4145-8279-5C38097BF473 Q37581359-93D2A79A-2261-4045-8CCA-CD2A4756ABE8 Q37735041-32BA68CD-C8D6-4828-8720-9EEB47A7F887 Q38103946-27E34388-063F-416A-868B-B81617925457 Q38188582-00B460C8-E92B-43CC-ABA2-53C2D5C559AE Q38201654-1554C203-A962-46FF-BE03-8912CAD41B3E Q38207014-B96C8AA4-3E3B-4F8F-A766-629D2E5F4B9E Q38366584-628278E7-B502-4D3E-9ACD-DE3DFD1C3A2C Q38408876-CA65ED52-F587-4DDB-982A-CBC7152FBE00 Q38552383-7FB618DA-75AF-4720-8537-75467F966334 Q40785415-E8E744AA-1CFE-443A-8A73-8DA6D2FDD58F Q40989838-F2C89421-9E5D-4B91-A934-9AF3052A713C

P2860

Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma.

http://www.wikidata.org/entity/Q35289603

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Clinical and prognostic implic ...... with hepatocellular carcinoma.

@ast

Clinical and prognostic implic ...... with hepatocellular carcinoma.

@en

type

label

Clinical and prognostic implic ...... with hepatocellular carcinoma.

@ast

Clinical and prognostic implic ...... with hepatocellular carcinoma.

@en

prefLabel

Clinical and prognostic implic ...... with hepatocellular carcinoma.

@ast

Clinical and prognostic implic ...... with hepatocellular carcinoma.

@en

P1433

Q35289603-17C3CBEC-79DC-4F96-90FE-02F4CA3C80E5

P1476

Q35289603-801C8C92-5A15-4D91-B0E8-28840A3AC789

P2093

Q35289603-1FD36138-68D9-4706-86B9-5451A1850392

Q35289603-3B0C64EA-105C-4425-B9F5-268A67F34E87

Q35289603-3D292DBC-41E5-47B2-9E13-07401D64287C

Q35289603-6218432B-CFF2-47F5-B7C9-5ED920145578

Q35289603-71EEA8B7-02E0-4569-BA1E-B6AB8E2ABD2B

Q35289603-798EF069-BB31-4536-959C-3B66D00637D0

Q35289603-7D1EC9A3-9B7E-4ADD-887C-D6E5F16E149D

Q35289603-A901C383-9240-4657-9267-FBB4336BF434

Q35289603-AF5EE8B9-3E0A-4D47-A4FF-452D81AD9070

Q35289603-C5F5EB6F-68F8-44AD-952E-E7A371B3E52C

P2860

Q35289603-013B03C2-0746-4B21-AB62-7748FF04CD5F

Q35289603-1207CD2B-5615-4BE6-9FA7-22CB39A8055A

Q35289603-1717A659-7963-443C-A33B-1DF95619AB4C

Q35289603-1BF996CC-05B5-4B39-96AD-2F80F8DCCAD0

Q35289603-2265EA36-34CC-4A95-8A38-7F915F4DD1DA

Q35289603-24E0B762-F71D-4D03-B950-5B302DA10AC2

Q35289603-2935E5B4-1C6D-4595-984B-1542CD7195F9

Q35289603-293B2F7A-1D64-46A6-B8F7-4A6B261AAF2E

Q35289603-394349F9-3491-4DB4-B1C5-AE0C89AFE390

Q35289603-471DD03A-AB4A-41F3-B9F9-F489781E428A

P304

Q35289603-32A484E1-6ED7-43D7-B46D-AA881CA92534

P31

Q35289603-0909748F-6499-4380-9C6C-F41981AB4AFB

P356

Q35289603-78A2880F-924A-44A1-B60E-8C7F587120C3

P407

Q35289603-FF9AE6A6-C80B-41DA-BA54-30DE0D2414D7

P433

Q35289603-74F3577F-0A4B-4423-97DC-5BFF9FDD4804

P478

Q35289603-2E1182D1-EEAD-4A74-A0DD-E145E307F799

P50

Q35289603-5063CEF5-239D-4668-AEFF-33EEAB0E8495

P577

Q35289603-1E759AB9-20FF-4F29-B5F8-2D57693965D5

P5875

Q35289603-A1DFB4B5-9F30-44CA-AAE2-80C07F5804F9

P698

Q35289603-89973ED2-B1B5-44A4-B24A-DFCCD0CEAB6B

P921

Q35289603-229AAC02-9F26-4F36-9948-416A6965DBCA

Q35289603-3B16332E-E32F-4B72-BE8F-91AB7C1C6D9D

P932

Q35289603-EAC9902E-169B-496A-AFD2-EE08E83C1AFA

P356

JCO.2011.36.0636

P1433

Journal of Clinical Oncology

P1476

Clinical and prognostic implic ...... with hepatocellular carcinoma.

@en

P2093

Adnan M Siddiqui

http://www.w3.org/2001/XMLSchema#string

Ahmed O Kaseb

http://www.w3.org/2001/XMLSchema#string

E Lin

http://www.w3.org/2001/XMLSchema#string

Eddie K Abdalla

http://www.w3.org/2001/XMLSchema#string

James L Abbruzzese

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Morris

http://www.w3.org/2001/XMLSchema#string

Lianchun Xiao

http://www.w3.org/2001/XMLSchema#string

Manal M Hassan

http://www.w3.org/2001/XMLSchema#string

Sunil Krishnan

http://www.w3.org/2001/XMLSchema#string

Thomas A Aloia

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hepatocellular carcinoma

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

Prognosis of hepatocellular carcinoma: the BCLC staging classification

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.

V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials.

Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).

I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score.

Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients.

Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD.

Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma patients with cirrhosis

P304

3892-3899

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.36.0636

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Nicolas Vauthey

P577

2011-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51641295

http://www.w3.org/2001/XMLSchema#string

P698

21911725

http://www.w3.org/2001/XMLSchema#string

P921

P932

3189091

http://www.w3.org/2001/XMLSchema#string